SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is under pressure as traders worry that post-election calls for tighter AI regulation could slow data-center construction and weaken demand for AI-related memory chips. The community is split between those who see the selloff as an overreaction with memory demand intact and those warning that slower AI spending or a peak in the memory cycle could bring further declines.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is under pressure amid fears that the post-election political landscape could bring tighter AI regulation and data-center permitting delays, slowing infrastructure spending; concerns about the sustainability of AI capex and circular financing add to the debate. Traders are split between seeing a broader risk to chip demand and treating the selloff as an overreaction, arguing that projects and GPU demand could shift elsewhere.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is selling off with memory and AI-linked chip stocks as Democratic gains in Congress fuel trader concerns that tighter AI and data-center rules could slow future infrastructure buildouts. Bulls call the move an overreaction and point to continued memory demand, while bears warn of prolonged weakness in the AI trade and memorys cyclical risks.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention amid a sharp semiconductor selloff, with traders debating whether fears of tighter AI and data-center regulation after the midterm results are justified; weak reactions to chip-company earnings are also cited. Some see the decline as an overdone, oversold move and are buying for a bounce, while others expect more downside and warn that the funds 3x leverage magnifies volatility.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snaps quarterly report missed revenue and daily-active-user expectations, while advertising growth remained sluggish, prompting a sharp post-earnings selloff and criticism of management. Traders are split: bears focus on weak user and ad trends and the shift toward MAUs as a reported metric, while bulls point to improved profitability, cash flow, subscriptions, and the companys outlook.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Q3 results showing strong commercial growth and expanding gross margins have drawn attention, though Iovance reaffirmed rather than raised its full-year outlook. Traders praise the improving business trajectory, while others point to the muted share-price reaction and lingering uncertainty around the NSCLC data and filing timeline.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsiuss Q3 results beat expectations, with growth led by Alani Nu and international sales, but traders are debating whether that strength can offset weakness in the core Celsius brand and compressed margins. Reactions are broadly positive on the sales beat, tempered by concerns about profitability and the durability of growth.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Reported Lundbeck takeover interest has fueled heavy speculation about a possible bid or bidding war, though Xeris has said it is not for sale and traders disagree on whether a deal is likely. The debate is reinforced by optimism about Recorlevs growth and XP-8121s Phase 3 prospects, alongside skepticism about the long development timeline.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unitys quarterly results beat expectations, marking its first GAAP-profitable quarter, with upbeat guidance and strong Vector advertising growth driving attention. Traders largely celebrated the results as a potential business inflection, while some questioned whether the rally was excessive and how sustainable the growth will be.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X ETF

SOXS is drawing attention as traders use the inverse semiconductor ETF to trade a sharp chip-sector selloff, with many linking the weakness to midterm results and concerns about potential AI and data-center policy changes. Some expect further downside in semiconductors, while others anticipate a relief rally and warn that SOXSs daily leverage makes it risky to hold through volatile reversals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Perceptive Advisors Llc Sells 31,810 Shares of Lyra Therapeutics (NASDAQ:LYRA) Stock

Lyra Therapeutics, Inc. (NASDAQ:LYRA - Get Free Report) major shareholder Perceptive Advisors Llc sold 31,810 shares of the stock in a transaction on Thursday, November 13th. The stock was sold at an...

Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates

Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of +43.48% and -77.27%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Lyra Therapeutics (NASDAQ:LYRA) Major Shareholder Perceptive Advisors Llc Sells 32,149 Shares

Lyra Therapeutics, Inc. (NASDAQ:LYRA - Get Free Report) major shareholder Perceptive Advisors Llc sold 32,149 shares of Lyra Therapeutics stock in a transaction on Thursday, November 6th. The shares...

Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates

Assertio (ASRT) delivered earnings and revenue surprises of +237.50% and +83.86%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Dentsply International (XRAY) Lags Q3 Earnings Estimates

Dentsply (XRAY) delivered earnings and revenue surprises of -17.78% and +0.27%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -150.00% and -0.91%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Lyra Therapeutics To Conduct One More Trial For Chronic Rhinosinusitis Treatment Candidate

Equity

The company stated that the design of the new trial will be based on the learnings from the previous trials, in addition to FDA feedback.

Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates

Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of +4.84% and +26.21%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -100.00% and -1.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat (ENT) diseases. The firm's proprietary XTreo platform delivers medicines directly to targeted sites. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer on November 21, 2005 and is headquartered in Watertown, MA.

Lyra Therapeutics Inc

Neutral Sentiment

Shares of Lyra Therapeutics, Inc. (LYRA) rose 19% on Monday after the company stated that it intends to proceed with an additional clinical trial for its lead product candidate for chronic rhinosinusitis.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/06/3161569/0/en/Lyra-Therapeutics-Announces-Clinical-Plan-for-LYR-210-and-Late-Breaking-Oral-Presentation-of-Phase-3-ENLIGHTEN-2-Study.html">stated</a> that the U.S. Food and Drug Administration confirmed at a meeting in September that an additional trial was required for the submission of a new drug application for LYR-210 in the treatment of chronic rhinosinusitis without nasal polyps. The design of the new trial will be based on the learnings from previous trials, as well as feedback from the FDA, the company said."We look forward to continuing the development of LYR-210 as a six-month treatment option for millions of patients who do not respond to standard CRS medical management,” CEO Maria Palasis said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LYRA">LYRA stock</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1364/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_06_at_2_16_16_PM_png_84207e66c2.webp" alt="LYRA's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Oct. 06, 2025 | Source: Stocktwits" width="1364" height="130"><figcaption>LYRA's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Oct. 06, 2025 | Source: Stocktwits</figcaption></figure>In June, Lyra announced positive results from a late-stage trial of LYR-210 in adult patients with CRS. It demonstrated statistically significant improvement compared to sham control in key symptoms of chronic rhinosinusitis, such as nasal obstruction, nasal discharge, and facial pain/pressure at week 24 in patients with or without nasal polyps in the trial.LYR-210 is an investigational bioabsorbable nasal implant for the treatment of chronic rhinosinusitis (CRS) in patients who have failed current therapies and require further intervention. It is designed to be inserted in a simple, in-office procedure and intended to deliver six months of continuous anti-inflammatory therapy, mometasone furoate, to the sinonasal passages for the treatment of CRS.LYRA stock is down 19% this year and approximately 25% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spruce-biosciences-stock-more-than-quadruples-after-breakthrough-therapy-designation-to-therapy-for-rare-fatal-genetic-disease/ch6R7WfR3gl">Why Did Spruce Biosciences Stock Quadruple Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Current Price	$0.19
Prev Close	$0.19
Open	$0.03
Dividend Yield	0.00%
50-Day Moving Average	$0.1799
Beta	-2.47
Avg. Volume	1,107.86
PE Ratio	-0.01

52-Week High	$5.65
52-Week Low	$0.0004
Market Capitalization	$337,228.00
EPS (Annual)	-$18.62
Price to Book	-0.03
Revenue Per Employee	$14,740.74

Feed

News

Sentiment

Earnings

Fundamentals

Info

LYRA Fundamentals